Trial
NCT04636801
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chiesi Farmaceutici S.p.A.
Collaborators
—
Condition
Chronic Obstructive Pulmonary Disease
Intervention
Experimental: CHF6001 1600µg
Why stopped
Strategic decision by Sponsor; not due to safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-17